RxDoctor Payments Data

Pamela Bartell, DO

Family Medicine · Midlothian, VANPI 1356638860

Payments from drug & device makers

$6,488in general payments, 2019–2025

Across 431 payments — averaging $15.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Amgen$557
  • Novo Nordisk$449
  • Lilly USA, LLC$432
  • AstraZeneca$414
  • Boehringer Ingelheim$392
  • plus $2K from 35 others

What the payments were for

  • Food & beverage$6,463100%
  • Education$250%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,488 in reported general payments places this provider in the 85th percentile of 2,553 family medicine providers in Virginia.

See all family medicine providers in Virginia

Medicare billing

Part B allowed, 2024
$76,768
Medicare patients
188
Services billed
1,171

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin65$58,269
TrulicityDulaglutide47$52,219
OzempicSemaglutide30$28,472
EliquisApixaban25$25,548
MounjaroTirzepatide16$21,883
Repatha SureclickEvolocumab11$17,021
JanuviaSitagliptin Phosphate16$11,971
FarxigaDapagliflozin Propanediol21$11,503
NexletolBempedoic Acid12$4,722
Levothyroxine Sodium144$2,260
Rosuvastatin Calcium224$2,193
Ezetimibe40$1,885
SynthroidLevothyroxine Sodium27$1,415
Losartan Potassium120$1,217
Duloxetine Hcl36$1,191

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$432$74,10263 claims
Boehringer IngelheimJardiance$392$58,26965 claims
Novo NordiskOzempic$449$28,47230 claims
PfizerEliquis$287$25,54825 claims
MerckJanuvia$172$11,97116 claims
AstraZenecaFarxiga$414$11,50321 claims
Esperion Therapeutics, Inc.Nexletol$50$4,72212 claims
AbbVieSynthroid$1,963$1,41527 claims
Teva Pharmaceuticals USA, Inc.Acyclovir$105$44513 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,553 family medicine providers in Virginia.

Other family medicine in Midlothian

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →